scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.JTHO.2016.12.024 |
P698 | PubMed publication ID | 28093244 |
P50 | author | Caicun Zhou | Q114358334 |
P2093 | author name string | Kai Chen | |
Tao Jiang | |||
Fei Zhou | |||
Xue Wu | |||
Yang W Shao | |||
Xiaoling Tong | |||
Songbing Qin | |||
Wenxiang Shen | |||
P433 | issue | 6 | |
P304 | page(s) | e65-e68 | |
P577 | publication date | 2017-01-16 | |
P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
P1476 | title | Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. | |
P478 | volume | 12 |
Q91762027 | A "triple whammy" in adenocarcinoma lung |
Q89497162 | Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018 |
Q61810143 | Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives |
Q49643911 | Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature. |
Q92493465 | Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer |
Q60303033 | Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence |
Q90429716 | Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M |
Q47146662 | Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer |
Q60301224 | Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report |
Q47777525 | Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study |
Q38682189 | Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms |
Q57177486 | Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective |
Q61797228 | Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report |
Q40989687 | Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion |
Q55191884 | Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials. |
Q58750993 | SOX5 induces lung adenocarcinoma angiogenesis by inducing the expression of VEGF through STAT3 signaling |
Q52655063 | SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition. |
Q100636214 | The next tier of EGFR resistance mutations in lung cancer |
Q49887956 | Third generation EGFR TKIs: current data and future directions |
Q52332839 | Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. |
Q88682201 | Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance |
Search more.